226 related articles for article (PubMed ID: 35476550)
41. Triple-Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant Chemotherapy.
Paula B; Crocamo S; de Sousa CAM; Valverde P; Rezende F; Abdelhay E
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892013
[TBL] [Abstract][Full Text] [Related]
42. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
43. Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.
Ibrahim E; Al-Gahmi AM; Zeenelin AA; Zekri JM; Elkhodary TR; Gaballa HE; Fawzy EE; El sayed ME; Alzahrani MS
Med Oncol; 2009; 26(3):372-8. PubMed ID: 19034706
[TBL] [Abstract][Full Text] [Related]
44. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
Lv M; Li B; Li Y; Mao X; Yao F; Jin F
Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
[TBL] [Abstract][Full Text] [Related]
45. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.
de Moura Leite L; Cesca MG; Tavares MC; Santana DM; Saldanha EF; Guimarães PT; Sá DDS; Simões MFE; Viana RL; Rocha FG; Loose SK; Silva SF; Pirolli R; Fogassa CAZ; Mattos BRS; Campos FAB; Sanches SM; de Lima VCC; Pondé NF
Breast Cancer Res Treat; 2021 Nov; 190(1):155-163. PubMed ID: 34409551
[TBL] [Abstract][Full Text] [Related]
46. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
[TBL] [Abstract][Full Text] [Related]
47. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
[TBL] [Abstract][Full Text] [Related]
48. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
Meyers MO; Klauber-Demore N; Ollila DW; Amos KD; Moore DT; Drobish AA; Burrows EM; Dees EC; Carey LA
Ann Surg Oncol; 2011 Oct; 18(10):2851-7. PubMed ID: 21442348
[TBL] [Abstract][Full Text] [Related]
49. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
Tarantino P; Jin Q; Tayob N; Jeselsohn RM; Schnitt SJ; Vincuilla J; Parker T; Tyekucheva S; Li T; Lin NU; Hughes ME; Weiss AC; King TA; Mittendorf EA; Curigliano G; Tolaney SM
JAMA Oncol; 2022 Aug; 8(8):1177-1183. PubMed ID: 35737367
[TBL] [Abstract][Full Text] [Related]
50. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Carey LA; Berry DA; Cirrincione CT; Barry WT; Pitcher BN; Harris LN; Ollila DW; Krop IE; Henry NL; Weckstein DJ; Anders CK; Singh B; Hoadley KA; Iglesia M; Cheang MC; Perou CM; Winer EP; Hudis CA
J Clin Oncol; 2016 Feb; 34(6):542-9. PubMed ID: 26527775
[TBL] [Abstract][Full Text] [Related]
51. Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?
von Minckwitz G; Fontanella C
Breast; 2013 Aug; 22 Suppl 2():S149-51. PubMed ID: 24074777
[TBL] [Abstract][Full Text] [Related]
52. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
Precht LM; Lowe KA; Atwood M; Beatty JD
Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
[TBL] [Abstract][Full Text] [Related]
53. Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer.
Gülben K; Berberoğlu U; Kinaş V; Başkan E
Acta Chir Belg; 2014; 114(3):153-9. PubMed ID: 25102703
[TBL] [Abstract][Full Text] [Related]
54. Clinical implications of the intrinsic molecular subtypes of breast cancer.
Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
[TBL] [Abstract][Full Text] [Related]
55. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
[TBL] [Abstract][Full Text] [Related]
56. Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
Whitworth PW; Beitsch PD; Murray MK; Richards PD; Mislowsky A; Dul CL; Pellicane JV; Baron PL; Rahman RL; Lee LA; Dupree BB; Kelemen PR; Ashikari AY; Budway RJ; Lopez-Penalver C; Dooley W; Wang S; Dauer P; Menicucci AR; Yoder EB; Finn C; Blumencranz LE; Audeh W
JCO Precis Oncol; 2022 Sep; 6():e2200197. PubMed ID: 36108259
[TBL] [Abstract][Full Text] [Related]
57. Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer.
Liao GS; Dai MS; Hsu HM; Chu CH; Hong ZJ; Fu CY; Chou YC; Huang TC; Yu JC
Eur J Surg Oncol; 2017 Oct; 43(10):1855-1861. PubMed ID: 28756019
[TBL] [Abstract][Full Text] [Related]
58. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
[TBL] [Abstract][Full Text] [Related]
59. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
[TBL] [Abstract][Full Text] [Related]
60. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]